Citations

Clear

4 citation(s) found for "Brochet, Bruno".

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Rollot, Fabien , Mondot, Lydiane, Louapre, Céline , Page, Emmanuelle Le , Durand‐Dubief, Françoise , Labauge, Pierre, Bensa, Caroline , Thouvenot, Éric , Ciron, Jonathan , Bourre, Bertrand , Cabre, Philippe, Casez, Olivier , Ruet, Aurélie , Mathey, Guillaume , Berger, Éric , Moreau, Thibault, Khedr, A. Al, Derache, Nathalie, Guennoc, Anne‐Marie, Créange, Alain , Neau, Jean‐Philippe, Tourbah, Ayman , Camdessanché, Jean‐Philippe , Maarouf, Adil , Callier, Céline, Kantarci, Orhun H. , Sıva, Aksel , Azevedo, Christina , Makhani, Naila , Pelletier, Daniel , Investigators, RISC, SFSEP, and OFSEP, Pelletier, Daniel, Azevedo, Christina, Radji, Fataï, Morel, Nathalie, Grosset-Jeannin, Deborah, Ungureanu, Aurelian , Boyer, L, Suchet, Laurent , Elias, Zyad, Brochet, Bruno, Defer, Gilles , Branger, Pierre , Clavelou, Pierre, Taithe, Frédéric, Alkhedr, Adullatif, Fromont, Agnès, Hautecoeur, Patrick, Androdias, G. , Ionescu, Iuliana, Pelletier, Jean , Audoin, Bertrand , Labauge, Pierre, Debouverie, Marc, Laplaud, David, Wiertlevski, Sandrine, Bresch, Saskia , Castelnovo, Giovanni, Papeix, Caroline , Lubetzki, Catherine , Stankoff, Bruno, Fontaine, Bertrand , Giannesini, C. , Heinzleff, Olivier, Bourre, Bertrand, Gout, Olivier , Guegen, Antoine, Leray, Emmanuelle , Guennoc, Anne Marie , Broucker, T. de , Sehaki, Sabrina, Devys-Meyer, Nathalie, Bereau, Mathieu, Cappe, Chrystelle, Kounkou, Katy-Kim, Dumont, Émilie , Lescieux, Edwige, Protin, Alexia, Kane, Maty Diop, Boucher, Julie, Petit, Julie, Kasonde, Irène Tabellah, Vilmarrest, Aymeric de, Nicol, Marie , Malbezin, Muriel, Olaiz, Javier, Rigaud-Bully, Claire, Vukusic, Irena, Debard, Nadine, Cotton, François, Abdelalli, Amalle, Lelio, Bernadette Di, Pinna, Frédéric , Guillemin, Francis, Ziegler, Amandine, Zehrouni, Karima, Hodel, Jérôme , Wahab, Abir , Zedet, Mickaël, Fagniez, Ombeline, Laage, Clémence, Pottier, Corinne , Slesari, Iuliana, Sampaio, Mathilde, Rabois, Emilie, Castex, Cédric , Hébant, Benjamin , Guillaume, Maxime , Vimont, Christine, Muraz, Romain, Port, Damien Le, Henry, Carole , Berthe, Carole, Freitas, Noellie, Visneux, Vincent, Forestier, M., Beltran, S. , Meunier, Géraldine, Servan, Jérôme, Pico, Fernando, Chatagner, Virginie, Siva, Aksel , Thouvenot, Eric , Ciron, Jonathan , Durand-Dubief, Françoise , Lebrun‐Frénay, Christine , Mondot, Lydiane , Zéphir, Hélène , Laplaud, David , Seze, Jerome De , Bourre, Bertrand , Casez, Olivier , Clavelou, Pierre , Vermersch, Patrick , Cohen, Mikaël , Okuda, Darin T. , Vukusic, Sandra , Investigators, RISC, SFSEP, and OFSEP, Azevedo, Christina, Morel, Nathalie, Boyer, Latine, Ouallet, Jean‐Christophe , Clavelou, Pierre, Outteryck, Olivier , Hautecoeur, Patrick, Ayrignac, Xavier , Carra‐Dallière, Clarisse , Labauge, Pierre, Laplaud, David, Maillart, Elisabeth , Bourre, Bertrand, Michel, Laure , Magy, Laurent , Collongues, Nicolas , Biotti, Damien , Béreau, Matthieu , Casey, Romain , Muraz, Romain, Forestier, Melanie

Mayo Clinic

JAMA Network Open | October 17, 2021 | Volume: 4 | Issue: 10 | Pages: e2128271

10.1001/jamanetworkopen.2021.28271 | PMID 34633424 Get It

International consensus statement on the use of disease-modifying agents in multiple sclerosis
Freedman, M. S., Blumhardt, L. D., Comi, Giancarlo , Noseworthy, J H, Sandberg‐Wollheim, Magnhild, Brochet, Bruno , Sørensen, Per Soelberg

Mayo Clinic

Multiple Sclerosis Journal | March 4, 2009 | Volume: 8 | Issue: 1_suppl | Pages: 19-23

10.1177/135245850200800105 Get It

Objective:To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit.Methods:An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment.Results:A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available. Multiple Sclerosis (2002)8,19-23
International consensus statement on the use of disease-modifying agents in multiple sclerosis
Freedman, M. S., Blumhardt, L. D., Comı, Gıancarlo , Noseworthy, J H, Sandberg‐Wollheim, Magnhild, Sørensen, Per Soelberg , Group, Paris Workshop, Brochet, Bruno , Group, Paris Workshop

Mayo Clinic

Multiple Sclerosis Journal | July 27, 2002 | Volume: 8 | Issue: 1 | Pages: 19-23

10.1191/1352458502ms769oa | PMID 11936483 Get It

Objective: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods: An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment. Results: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.